Combination therapy of CLDN18 antibodies and chemotherapeutic drugs

Through the combined treatment of the antibody specifically recognized CLDN18.2 and 5-fluorouracil and oxaliplatin, the problems of poor tolerance of chemotherapy drugs and limited treatment effects were solved, and the treatment effect on CLDN18-positive tumors such as gastric cancer was significantly improved.

CN112888458BActive Publication Date: 2024-11-22CARSGEN LIFE SCI CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980065066.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-10-19
Filing Date
2019-09-29
Publication Date
2024-11-22
Estimated Expiration
2039-09-29

AI Technical Summary

Technical Problem

The existing chemotherapy drugs are highly cytotoxic and poor tolerant in the treatment of gastric cancer, which brings clinical application risks, and the combined treatment effect of antibodies targeting CLDN18.2 and chemotherapy drugs are limited.

Method used

By using a combination therapy method of specifically identifying CLDN18.2 with 5-fluorouracil or its prodrug, oxaliplatin or its prodrug, by administering antibodies specifically recognize CLDN18.2, 5-fluorouracil or its prodrug, Oxaliplatin or its prodrug, combined with cysanthene, is used to treat CLDN18-positive tumors.

Benefits of technology

It improves the therapeutic effect on CLDN18-positive tumors, reduces the side effects of chemotherapy drugs, enhances the patient's tolerance, and significantly inhibits tumor growth.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112888458B_ABST
    Figure CN112888458B_ABST
Patent Text Reader

Abstract

A method for treating CLDN18-positive tumors, wherein an antibody and a chemotherapeutic drug that specifically recognize CLDN18 are administered to an individual in need, wherein the chemotherapeutic drug is: 5-fluorouracil or its prodrug or its active metabolite, oxaliplatin or its prodrug or its active metabolite; or, 5-fluorouracil or its prodrug or its active metabolite, oxaliplatin or its prodrug or its active metabolite, and a taxane drug. A kit combination for treating CLDN18-positive tumors. Compared with the prior art, the treatment method and the kit combination have greatly enhanced tumor inhibition rates and have better anti-tumor effects. In addition, the use of chemotherapeutic drugs can be reduced, and the safety of medication and patient tolerance are improved.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to Chinese patent applications filed on September 30, 2018, with application number 201811159863.8, entitled “Combined therapy of antibodies against CLDN18.2 and chemotherapeutic drugs” and filed on October 19, 2018, with application number 201811224605.3, entitled “Combined therapy of antibodies against CLDN18 and chemotherapeutic drugs”. The contents of the prior applications are incorporated herein by reference in their entirety. Technical Field

[0002] The present invention belongs to the field of biomedicine, and specifically relates to a combined treatment of a CLDN18 antibody and a chemotherapeutic drug. Background Art

[0003] Gastric cancer is one of the most common cancers worldwide. According to statistics from the World Health Organization's cancer control program, 7 million people die from cancer each year, of which 700,000 are from gastric cancer.

[0004] Ganymed, a German biotechnology company, reported the use of a chemotherapy drug combination of EOX (epirubicin, oxaliplatin and capecitabine) and an antibody targeting Claudin18.2 to treat gastric cancer. EP2852408B also reported the use of a chemotherapy drug combination of EOF (epirubicin, 5-fluoropyrimidine and oxaliplatin) and an antibody targeting cell junction claudin (Claudin or CLDN) 18.2 to treat gastric cancer in mice.

[0005] However, since chemotherapy drugs usually have strong cytotoxicity and poor patient tolerance, the use of multiple chemotherapy drugs brings great risks in clinical application. Summary of the invention

[0006] The object of the present invention is to provide a combination therapy of a CLDN18 antibody and a chemotherapeutic drug, which is used to effectively treat diseases associated with the expression of CLD18A.

[0007] In a first aspect of the present invention, a method for treating CLDN18-positive tumors is provided, comprising administering an antibody that specifically recognizes CLDN18, 5-fluorouracil or a prodrug or an active metabolite thereof, and oxaliplatin or a prodrug or an active metabolite thereof, to an individual in need thereof; or administering an antibody that specifically recognizes CLDN18, 5-fluorouracil or a prodrug or an active metabolite thereof, oxaliplatin or a prodrug or an active metabolite thereof, and a taxane drug to an individual in need thereof.

[0008] In a specific embodiment, an antibody that specifically recognizes CLDN18, 5-fluorouracil or a prodrug thereof, and oxaliplatin or a prodrug thereof is administered to an individual in need thereof; or an antibody that specifically recognizes CLDN18, 5-fluorouracil or a prodrug thereof, oxaliplatin or a prodrug thereof, and a taxane drug is administered to an individual in need thereof.

[0009] In a specific embodiment, the prodrug of 5-fluorouracil is capecitabine.

[0010] In a specific embodiment, the CLDN18 is CLDN18.2.

[0011] In a specific embodiment, the antibody specifically recognizes CLDN18.2 but not CLDN18.1.

[0012] In a specific embodiment, the antibody against CLDN18, 5-fluorouracil or a prodrug or an active metabolite thereof, and oxaliplatin or a prodrug or an active metabolite thereof are administered in any order.

[0013] In a specific embodiment, 5-fluorouracil or a prodrug or an active metabolite thereof, oxaliplatin, and an antibody to CLDN18 are administered on the same day.

[0014] In a specific embodiment, the dosage of the CLDN18 antibody is 500 to 1200 mg / m 2 / time. In a preferred embodiment, 500-1000 mg / m 2 / time. In a preferred embodiment, 500-900 mg / m 2 / time. In a preferred embodiment, 600-800 mg / m 2 / Second-rate.

[0015] In a specific embodiment, the dosage of the CLDN18 antibody is 20 to 300 mg / kg / time. In a preferred embodiment, it is 20 to 100 mg / kg / time. In a preferred embodiment, it is 20-50 mg / kg / time.

[0016] In a specific embodiment, the dosage of 5-fluorouracil or its prodrug or its active metabolite is 300-900 mg / m 2 / Second-rate.

[0017] In one embodiment, 5-fluorouracil is administered at a dose of 300-800 mg / m 2 / Second-rate.

[0018] In one embodiment, capecitabine is administered at 600-700 mg / m 2 / time. In a preferred embodiment, 625 mg / m 2 / Second-rate.

[0019] In a specific embodiment, the dosage of 5-fluorouracil or its prodrug or its active metabolite is 50-70 mg / kg / time. In a preferred embodiment, 5-fluorouracil is administered at a dosage of 50-70 mg / kg / time. In a more preferred embodiment, 5-fluorouracil is administered at a dosage of 50-60 mg / kg / time.

[0020] In a specific embodiment, the dosage of oxaliplatin or its prodrug or its active metabolite is 50 to 300 mg / m 2 In a preferred embodiment, oxaliplatin 100-200 mg / m 2 In a more preferred embodiment, oxaliplatin 130 mg / m 2 / Second-rate.

[0021] In a specific embodiment, the dosage of oxaliplatin or its prodrug or its active metabolite is 1 to 10 mg / kg / time. In a preferred embodiment, oxaliplatin is administered at 1 to 5 mg / kg / time.

[0022] In a specific embodiment, the antibody that specifically recognizes CLDN18 is a humanized antibody or a chimeric antibody.

[0023] In a specific embodiment, the antibody that specifically recognizes CLDN18 comprises:

[0024] HCDR1 shown in the amino acid sequence of SEQ ID NO: 16, HCDR2 shown in the amino acid sequence of SEQ ID NO: 17, 40, or 41, HCDR3 shown in the amino acid sequence of SEQ ID NO: 18, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 19, LCDR2 shown in the amino acid sequence of SEQ ID NO: 20, LCDR3 shown in the amino acid sequence of SEQ ID NO: 21; or,

[0025] HCDR1 shown in the amino acid sequence of SEQ ID NO: 34, HCDR2 shown in the amino acid sequence of SEQ ID NO: 35 or 42, HCDR3 shown in the amino acid sequence of SEQ ID NO: 36, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 37, LCDR2 shown in the amino acid sequence of SEQ ID NO: 38, LCDR3 shown in the amino acid sequence of SEQ ID NO: 39; or,

[0026] HCDR1 shown in the amino acid sequence of SEQ ID NO: 22, HCDR2 shown in the amino acid sequence of SEQ ID NO: 23, HCDR3 shown in the amino acid sequence of SEQ ID NO: 24, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 25, LCDR2 shown in the amino acid sequence of SEQ ID NO: 26, LCDR3 shown in the amino acid sequence of SEQ ID NO: 27; or,

[0027] HCDR1 shown in the amino acid sequence of SEQ ID NO: 28, HCDR2 shown in the amino acid sequence of SEQ ID NO: 29, HCDR3 shown in the amino acid sequence of SEQ ID NO: 30, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 31, LCDR2 shown in the amino acid sequence of SEQ ID NO: 32, LCDR3 shown in the amino acid sequence of SEQ ID NO: 33; or,

[0028] HCDR1 shown in the amino acid sequence of SEQ ID NO:43, HCDR2 shown in the amino acid sequence of SEQ ID NO:44, HCDR3 shown in the amino acid sequence of SEQ ID NO:45, and LCDR1 shown in the amino acid sequence of SEQ ID NO:46, LCDR2 shown in the amino acid sequence of SEQ ID NO:47, LCDR3 shown in the amino acid sequence of SEQ ID NO:48; or,

[0029] HCDR1 shown by the amino acid sequence of SEQ ID NO:49, HCDR2 shown by the amino acid sequence of SEQ ID NO:50, HCDR3 shown by the amino acid sequence of SEQ ID NO:51, and LCDR1 shown by the amino acid sequence of SEQ ID NO:52, LCDR2 shown by the amino acid sequence of SEQ ID NO:53, and LCDR3 shown by the amino acid sequence of SEQ ID NO:54.

[0030] In a specific embodiment, the antibody that specifically recognizes CLDN18 comprises:

[0031] HCDR1 shown in the amino acid sequence of SEQ ID NO: 16, HCDR2 shown in the amino acid sequence of SEQ ID NO: 17 or 41, HCDR3 shown in the amino acid sequence of SEQ ID NO: 18, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 19, LCDR2 shown in the amino acid sequence of SEQ ID NO: 20, LCDR3 shown in the amino acid sequence of SEQ ID NO: 21; or,

[0032] HCDR1 shown by the amino acid sequence of SEQ ID NO:34, HCDR2 shown by the amino acid sequence of SEQ ID NO:35 or 42, HCDR3 shown by the amino acid sequence of SEQ ID NO:36, and LCDR1 shown by the amino acid sequence of SEQ ID NO:37, LCDR2 shown by the amino acid sequence of SEQ ID NO:38, LCDR3 shown by the amino acid sequence of SEQ ID NO:39; or

[0033] Such as HCDR1 shown in the amino acid sequence of SEQ ID NO: 43, HCDR2 shown in the amino acid sequence of SEQ ID NO: 44, HCDR3 shown in the amino acid sequence of SEQ ID NO: 45, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 46, LCDR2 shown in the amino acid sequence of SEQ ID NO: 47, and LCDR3 shown in the amino acid sequence of SEQ ID NO: 48.

[0034] In a specific embodiment, the antibody that specifically recognizes CLDN18 contains:

[0035] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 2, 9, or 10 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 1; or

[0036] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 12 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 11; or,

[0037] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 8 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 7; or,

[0038] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 14 or 15 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 13; or

[0039] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 4 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 3; or,

[0040] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 6 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 5; or

[0041] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 55 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 56; or

[0042] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 57 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 58; or

[0043] In a specific embodiment, the antibody that specifically recognizes CLDN18 contains:

[0044] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 2 or 10 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 1; or

[0045] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 12 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 11; or,

[0046] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 8 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 7; or,

[0047] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 14 or 15 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 13; or

[0048] The heavy chain variable region is represented by the amino acid sequence of SEQ ID NO:55 and the light chain variable region is represented by the amino acid sequence of SEQ ID NO:56.

[0049] In a preferred embodiment, the antibody that specifically recognizes CLDN18 contains:

[0050] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 12 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 11; or,

[0051] the heavy chain variable region set forth in the amino acid sequence of SEQ ID NO: 15 and the light chain variable region set forth in the amino acid sequence of SEQ ID NO: 13;

[0052] The heavy chain variable region is represented by the amino acid sequence of SEQ ID NO:55 and the light chain variable region is represented by the amino acid sequence of SEQ ID NO:56.

[0053] In a specific embodiment, the antibody that specifically recognizes CLDN18 is selected from:

[0054] (a) having a heavy chain encoded by the nucleotide sequence shown in SEQ ID NO: 59 and a light chain encoded by the nucleotide sequence shown in SEQ ID NO: 60; or,

[0055] (b) having a heavy chain amino acid sequence shown in SEQ ID NO: 64 and a light chain amino acid sequence shown in SEQ ID NO: 63.

[0056] In a specific embodiment, the CLDN18-positive tumors include: gastric cancer, pancreatic cancer, esophageal cancer, and lung cancer.

[0057] In a specific embodiment, the taxane drug is selected from paclitaxel, albumin-bound paclitaxel, and docetaxel; preferably, it is albumin-bound paclitaxel.

[0058] In the second aspect of the present invention, a kit combination for treating CLDN18-positive tumors is provided, the kit combination comprising kit A and kit B, wherein kit A comprises an antibody that specifically recognizes CLDN18, and kit B comprises a chemotherapeutic drug, wherein the chemotherapeutic drug is: 5-fluorouracil or a prodrug or an active metabolite thereof, oxaliplatin or a prodrug or an active metabolite thereof; or, 5-fluorouracil or a prodrug or an active metabolite thereof, oxaliplatin or a prodrug or an active metabolite thereof, and a taxane drug.

[0059] In a specific embodiment, the kit A and kit B are administered to an individual in need, wherein kit B comprises 5-fluorouracil or a prodrug thereof, and oxaliplatin or a prodrug thereof; or kit A and kit B are administered to an individual in need, wherein kit B comprises 5-fluorouracil or a prodrug thereof, oxaliplatin or a prodrug thereof, and a taxane.

[0060] In a specific embodiment, the prodrug of 5-fluorouracil is capecitabine.

[0061] In a specific embodiment, the CLDN18 is CLDN18.2.

[0062] In a specific embodiment, the antibody specifically recognizes CLDN18.2 but not CLDN18.1.

[0063] In a specific embodiment, the time of administration of Kit A and Kit B is not particular.

[0064] In a specific embodiment, kit B comprising 5-fluorouracil or a prodrug or an active metabolite thereof, oxaliplatin, and kit A comprising an antibody to CLDN18 are administered on the same day.

[0065] In a specific embodiment of the drug kit A, the dosage of the CLDN18 antibody is 500-1200 mg / m 2 / time. In a preferred embodiment, 500-1000 mg / m 2 / time. In a preferred embodiment, 500-900 mg / m 2 / time. In a preferred embodiment, 600-800 mg / m 2 / Second-rate.

[0066] In a specific embodiment of the drug kit A, the dosage of the CLDN18 antibody is 20-300 mg / kg / time. In a preferred example, it is 20-100 mg / kg / time. In a preferred example, it is 20-50 mg / kg / time.

[0067] In a specific embodiment of the kit B, the dosage of 5-fluorouracil or its prodrug or its active metabolite is 300-900 mg / m 2 / Second-rate.

[0068] In one embodiment, 5-fluorouracil is administered at a dose of 300-800 mg / m 2 / Second-rate.

[0069] In one embodiment, capecitabine is administered at 600-700 mg / m 2 / time. In a preferred embodiment, 625 mg / m 2 / Second-rate.

[0070] In a specific embodiment of the drug kit B, the dosage of 5-fluorouracil or its prodrug or its active metabolite is 50-70 mg / kg / time. In a preferred example, 5-fluorouracil is administered at a dosage of 50-70 mg / kg / time. In a more preferred example, 5-fluorouracil is administered at a dosage of 50-60 mg / kg / time.

[0071] In a specific embodiment of the kit B, the dosage of oxaliplatin or its prodrug or its active metabolite is 50 to 300 mg / m 2 In a preferred embodiment, oxaliplatin 100-200 mg / m 2 In a more preferred embodiment, oxaliplatin 130 mg / m 2 / Second-rate.

[0072] In a specific embodiment of the drug kit B, the dosage of oxaliplatin or its prodrug or its active metabolite is 1-10 mg / kg / time. In a preferred embodiment, oxaliplatin is administered at 1-5 mg / kg / time.

[0073] In one specific embodiment of the kit A, the antibody that specifically recognizes CLDN18 is a humanized antibody or a chimeric antibody.

[0074] In one specific embodiment of the drug kit A, the antibody that specifically recognizes CLDN18 comprises:

[0075] HCDR1 shown in the amino acid sequence of SEQ ID NO: 16, HCDR2 shown in the amino acid sequence of SEQ ID NO: 17, 40, or 41, HCDR3 shown in the amino acid sequence of SEQ ID NO: 18, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 19, LCDR2 shown in the amino acid sequence of SEQ ID NO: 20, or LCDR3 shown in the amino acid sequence of SEQ ID NO: 21; or

[0076] HCDR1 shown by the amino acid sequence of SEQ ID NO:34, HCDR2 shown by the amino acid sequence of SEQ ID NO:35 or 42, HCDR3 shown by the amino acid sequence of SEQ ID NO:36, and LCDR1 shown by the amino acid sequence of SEQ ID NO:37, LCDR2 shown by the amino acid sequence of SEQ ID NO:38, LCDR3 shown by the amino acid sequence of SEQ ID NO:39; or

[0077] HCDR1 shown in the amino acid sequence of SEQ ID NO:22, HCDR2 shown in the amino acid sequence of SEQ ID NO:23, HCDR3 shown in the amino acid sequence of SEQ ID NO:24, and LCDR1 shown in the amino acid sequence of SEQ ID NO:25, LCDR2 shown in the amino acid sequence of SEQ ID NO:26, LCDR3 shown in the amino acid sequence of SEQ ID NO:27; or

[0078] HCDR1 shown in the amino acid sequence of SEQ ID NO:28, HCDR2 shown in the amino acid sequence of SEQ ID NO:29, HCDR3 shown in the amino acid sequence of SEQ ID NO:30, and LCDR1 shown in the amino acid sequence of SEQ ID NO:31, LCDR2 shown in the amino acid sequence of SEQ ID NO:32, LCDR3 shown in the amino acid sequence of SEQ ID NO:33; or

[0079] HCDR1 shown in the amino acid sequence of SEQ ID NO:43, HCDR2 shown in the amino acid sequence of SEQ ID NO:44, HCDR3 shown in the amino acid sequence of SEQ ID NO:45, and LCDR1 shown in the amino acid sequence of SEQ ID NO:46, LCDR2 shown in the amino acid sequence of SEQ ID NO:47, LCDR3 shown in the amino acid sequence of SEQ ID NO:48; or

[0080] HCDR1 shown by the amino acid sequence of SEQ ID NO:49, HCDR2 shown by the amino acid sequence of SEQ ID NO:50, HCDR3 shown by the amino acid sequence of SEQ ID NO:51, and LCDR1 shown by the amino acid sequence of SEQ ID NO:52, LCDR2 shown by the amino acid sequence of SEQ ID NO:53, and LCDR3 shown by the amino acid sequence of SEQ ID NO:54.

[0081] In a specific embodiment, in the drug kit A, the antibody that specifically recognizes CLDN18 comprises:

[0082] HCDR1 shown in the amino acid sequence of SEQ ID NO: 16, HCDR2 shown in the amino acid sequence of SEQ ID NO: 17 or 41, HCDR3 shown in the amino acid sequence of SEQ ID NO: 18, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 19, LCDR2 shown in the amino acid sequence of SEQ ID NO: 20, LCDR3 shown in the amino acid sequence of SEQ ID NO: 21; or

[0083] HCDR1 shown by the amino acid sequence of SEQ ID NO: 34, HCDR2 shown by the amino acid sequence of SEQ ID NO: 35 or 42, HCDR3 shown by the amino acid sequence of SEQ ID NO: 36, and LCDR1 shown by the amino acid sequence of SEQ ID NO: 37, LCDR2 shown by the amino acid sequence of SEQ ID NO: 38, and LCDR3 shown by the amino acid sequence of SEQ ID NO: 39.

[0084] In one specific embodiment of the drug kit A, the antibody that specifically recognizes CLDN18 contains:

[0085] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 2, 9, or 10 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 1; or

[0086] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 12 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 11; or

[0087] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 8 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 7; or

[0088] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 14 or 15 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 13; or

[0089] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 4 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 3; or

[0090] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 6 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 5; or

[0091] The heavy chain variable region set forth in the amino acid sequence of SEQ ID NO: 55 and the light chain variable region set forth in the amino acid sequence of SEQ ID NO: 56; or

[0092] The heavy chain variable region set forth in the amino acid sequence of SEQ ID NO: 57 and the light chain variable region set forth in the amino acid sequence of SEQ ID NO: 58; or

[0093] In one of the drug kits A of a specific embodiment, the antibody that specifically recognizes CLDN18 contains:

[0094] The heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 2 or 10 and the light chain variable region represented by the amino acid sequence of SEQ ID NO: 1; or

[0095] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 12 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 11; or

[0096] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 8 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 7; or

[0097] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 14 or 15 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 13; or

[0098] The heavy chain variable region is represented by the amino acid sequence of SEQ ID NO:55 and the light chain variable region is represented by the amino acid sequence of SEQ ID NO:56.

[0099] In a preferred embodiment of the drug kit A, the antibody that specifically recognizes CLDN18 contains:

[0100] The heavy chain variable region shown by the amino acid sequence of SEQ ID NO: 12 and the light chain variable region shown by the amino acid sequence of SEQ ID NO: 11; or

[0101] the heavy chain variable region set forth in the amino acid sequence of SEQ ID NO: 15 and the light chain variable region set forth in the amino acid sequence of SEQ ID NO: 13;

[0102] The heavy chain variable region is represented by the amino acid sequence of SEQ ID NO:55 and the light chain variable region is represented by the amino acid sequence of SEQ ID NO:56.

[0103] In one of the drug kits A in a specific embodiment, the antibody that specifically recognizes CLDN18 is selected from:

[0104] (a) having a heavy chain encoded by the nucleotide sequence shown in SEQ ID NO: 59 and a light chain encoded by the nucleotide sequence shown in SEQ ID NO: 60; or,

[0105] (b) having a heavy chain amino acid sequence shown in SEQ ID NO: 64 and a light chain amino acid sequence shown in SEQ ID NO: 63.

[0106] In a specific embodiment, the CLDN18-positive tumors include: gastric cancer, pancreatic cancer, esophageal cancer, and lung cancer.

[0107] In the medicine kit B of a specific embodiment, the taxane drug is selected from paclitaxel, albumin-bound paclitaxel, and docetaxel; preferably, it is albumin-bound paclitaxel.

[0108] In the third aspect of the present invention, a pharmaceutical composition for treating CLDN18-positive tumors is provided, wherein the pharmaceutical composition comprises an antibody that specifically recognizes CLDN18 and a chemotherapeutic drug, wherein the chemotherapeutic drug is the 5-fluorouracil or its prodrug or its active metabolite, oxaliplatin or its prodrug or its active metabolite as described above; or, 5-fluorouracil or its prodrug or its active metabolite, oxaliplatin or its prodrug or its active metabolite, and a taxane drug; and the antibody that specifically recognizes CLDN18 is the antibody described above.

[0109] In a fourth aspect of the present invention, a use of the above-mentioned drug kit combination or the above-mentioned drug composition in the preparation of a drug for treating CLDN18-positive tumors is provided.

[0110] In a fourth aspect of the present invention, the above-mentioned kit combination or pharmaceutical composition is provided for treating CLDN18-positive tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0111] Figure 1 This is a statistical chart of tumor volume in BALB / c nude mice bearing the human gastric cancer PDX-GA0006 model after being treated with different treatment regimens;

[0112] Figure 2 This is a statistical chart of the body weight of BALB / c nude mice bearing the human gastric cancer PDX-GA0006 model after being treated with different treatment regimens;

[0113] Figure 3 These are photos of tumors in BALB / c nude mice bearing the human gastric cancer PDX-GA0006 model after being treated with different treatment regimens;

[0114] Figure 4 This is a statistical chart of tumor weight in BALB / c nude mice bearing human gastric cancer PDX-GA0006 model after different treatment regimens. Note: Compared with the vehicle group, * indicates P≤0.05, ** indicates P≤0.01, and *** indicates P≤0.001;

[0115] Figure 5 The effects of different doses of the antibody on antitumor effects are shown;

[0116] Figure 6 The effects of different doses of antibodies on mouse body weight are shown. DETAILED DESCRIPTION

[0117] After in-depth research and repeated experiments, the inventors have obtained a method for treating tumors by combining antibodies targeting CLDN18.2, 5-fluoropyrimidine, and oxaliplatin. The tumors are tumors expressing claudin 18A2, especially gastric cancer, pancreatic cancer, esophageal cancer, and lung cancer.

[0118] The antibody of the present invention is an antibody that specifically binds to an epitope present on claudin 18A2 (CLDN18A2), including polyclonal antibodies and monoclonal antibodies, preferably monoclonal antibodies. The monoclonal antibodies covered by the present invention include IgA, IgG1-4, IgE, IgM and IgD antibodies. In one embodiment, the antibody is an IgG1 antibody. In addition, in some other optional schemes, the antibody may also be an IgG3 antibody, such as an IgG3K or IgG3λ isotype; it may also be an IgG4 antibody, such as an IgG4K or IgG4λ isotype; it may also be an IgA1 or IgA2 antibody or an IgM antibody. In certain embodiments, the CLD18A2 antibody is administered at a dose of 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 / kg / time; 1, 2, 3, 4, 5, 6 or 7 times per week; injected for 1 week, or continuously injected for 2, 3, 4, 5 or 6 weeks. In certain embodiments, the CLD18A2 antibody is administered at a dose of 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1050, 1100, 1150, 1200 mg / m 2 / time; 1, 2, 3, 4, 5 or 6 times per week; injection for 1 week, or continuous injection for 2, 3, 4, 5 or 6 weeks.

[0119] In order to make the present invention more easily understood, some terms are defined below.

[0120] The term "CLDN18.2" includes isoforms, mammalian (eg, human) CLDN18.2, post-translationally modified variants of human CLDN18.2, isoforms and interspecies homologs and analogs containing at least one common epitope with CLDN18.2. The amino acid sequence of CLDN18.2 (eg, human CLDN18.2) is known in the art, as shown in the NCBI database. The terms "CLDN18A2", "CLDN18.2" and "cell junction claudin 18.2" herein are used interchangeably, and the terms "CLDN18A1", "CLDN18.1" and "cell junction claudin 18.1" are used interchangeably.

[0121] The term "oxaliplatin" herein refers to the compound [(1R, 2R)-cyclohexane-1,2-diamine] (oxalic acid (2-)-O,O') platinum. In certain embodiments, the oxaliplatin is injected at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mg / kg / time per injection, 1, 2, 3, 4, 5, 6 or 7 times per week, injected for 1 week, or continuously injected for 2, 3, 4, 5 or 6 weeks. In certain embodiments, the oxaliplatin is injected at 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 mg / m 2 / times, 1, 2, 3, 4, 5, 6 or 7 times a week, for 1 week, or continuous injections for 2, 3, 4, 5 or 6 weeks.

[0122] The term "5-fluoropyrimidine" as used herein refers to the compound 5-fluoro-1H-pyrimidine-2,4-dione. In certain embodiments, the administration amount of 5-fluorouracil or its prodrug or its active metabolite is 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70 mg / kg / time, 1, 2, 3, 4, 5, 6, or 7 times a week, injected for 1 week, or continuously injected for 2, 3, 4, 5 or 6 weeks; in certain embodiments, the administration amount of 5-fluorouracil or its prodrug or its active metabolite is 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900 mg / m 2 / times, 1, 2, 3, 4, 5, 6, or 7 times per week, injected for 1 week, or continuously injected for 2, 3, 4, 5 or 6 weeks. In certain embodiments, the prodrug of 5-fluorouracil is capecitabine. In certain embodiments, the amount of capecitabine or its prodrug or its active metabolite administered is 600, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680, 685, 690, 695, 700 mg / m 2 / times, 1, 2, 3, 4, 5, 6, or 7 times per week, for 1 week, or continuous injections for 2, 3, 4, 5, or 6 weeks.

[0123] The term "epirubicin" herein refers to the compound 10-[(3-amino-2,3,6-trideoxy-AL-alpha-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-methoxy-(8S-CIS)-tetracene-5,12-dione.

[0124] The term "antibody" refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, or an antigen-binding fragment thereof. The term "antibody" also includes all recombinant forms of antibodies (particularly the antibodies described herein), such as antibodies expressed in prokaryotic cells, unglycosylated antibodies, and antibody fragments that bind to antigens and derivatives described below. Each heavy chain consists of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. Each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region. VH and VL can be further subdivided into hypervariable regions called complementarity determining regions (CDRs), which are interspersed in more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant regions of antibodies mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.

[0125] The term "monoclonal antibody" as used herein refers to a preparation of antibody molecules of single molecular composition. Monoclonal antibodies display a single binding specificity and affinity for a particular epitope. In one embodiment, monoclonal antibodies are produced by hybridomas comprising B cells from non-human animals (e.g., mice) fused with biochemical cells.

[0126] The antibodies described herein may be recombinant antibodies, which include all antibodies prepared, expressed, created or isolated by recombinant means, such as (a) antibodies isolated from animals (such as mice) whose immunoglobulin genes are transgenic or transchromosomal or hybridomas prepared therefrom, (b) antibodies isolated from host cells transformed to express antibodies (such as transfectomas), (c) antibodies isolated from recombinant combinatorial antibody libraries, and (d) antibodies prepared, expressed, created or isolated by any other means involving splicing of immunoglobulin gene sequences into DNA sequences.

[0127] The term "humanized antibody" herein refers to a CDR sequence derived from the germline of another mammalian species (e.g., mouse) that is grafted onto a human framework sequence. Additional framework region modifications may also be performed in human framework sequences and CDR sequences derived from the germline of another mammalian species.

[0128] The term "chimeric antibody" herein refers to an antibody in which the variable region sequence is derived from one species and the constant region sequence is derived from another species, for example, an antibody in which the variable region sequence is derived from a mouse antibody and the constant region sequence is derived from a human antibody.

[0129] The term "Fab" or "Fab region" herein includes polypeptides comprising VH, CH1, VL and CL immunoglobulin domains. Fab may refer to this region isolated, or to this region in the context of a full-length antibody or antibody fragment. The term "Fc" or "Fc region" herein includes polypeptides comprising antibody constant regions other than the first constant region immunoglobulin domain. Thus, Fc refers to the last two constant region immunoglobulin domains of IgA, IgD and IgG, and the last three constant region immunoglobulin domains of IgE and IgM, and the flexible hinge at the N-terminus of these domains. For IgA and IgM, Fc may include a J chain. For IgG, Fc includes immunoglobulin domains Cγ2 and Cγ3 and a hinge between Cγ1 and Cγ2. Although the boundaries of the Fc region may vary, the human IgG heavy chain Fc region is generally defined as comprising residues C226 or P230 at its carboxyl terminus, wherein numbering is according to the EU index of Kabat. For human IgG1, Fc is defined herein as comprising residues P232 to its carboxyl terminus, wherein numbering is according to the EU index as in Kabat. Fc may refer to this region in isolation, or to this region in the context of an Fc polypeptide, such as an antibody.

[0130] The term "hinge" or "hinge region" or "antibody hinge region" herein includes a flexible polypeptide of amino acids comprised between the first and second constant domains of an antibody. Structurally, the IgGCH1 domain ends at EU position 220 and the IgGCH2 domain begins at residue EU position 237. Thus, for IgG, the antibody hinge is defined herein as including positions 221 (D221 of IgG1) to 231 (A231 of IgG1), wherein numbering is according to the EU index of Kabat.

[0131] The term "variant" as used herein includes antibody sequences that differ from the parent antibody sequence due to at least one amino acid modification compared to the parent antibody. The variant antibody sequence herein preferably has at least about 80%, preferably at least about 90%, and more preferably at least about 95% amino acid sequence identity with the parent antibody sequence. Antibody variants may refer to the antibody itself, a composition comprising the parent antibody, or an amino acid sequence encoding the same.

[0132] The term "amino acid modification" herein includes amino acid substitutions, insertions and / or deletions in a polypeptide sequence. "Amino acid substitution" or "substitution" herein means replacing an amino acid at a specific position in a parent polypeptide sequence with another amino acid. For example, substitution R94K means that the arginine at position 94 is replaced by lysine, which is a heavy chain variable framework region variant. For the previous example, 94K means replacing position 94 with lysine. For the purposes of this article, multiple substitutions are usually separated by slashes. For example, R94K / L78V refers to a double variant comprising substitutions R94K and L78V. "Amino acid insertion" or "insertion" as used herein means adding an amino acid at a specific position in a parent polypeptide sequence. For example, insertion-94 means insertion at position 94. "Amino acid deletion" or "deletion" as used herein means removing an amino acid at a specific position in a parent polypeptide sequence. For example, R94- means deleting the arginine at position 94.

[0133] All immunoglobulin heavy chain constant region positions discussed herein are numbered according to the EU index of Kabat (Kabat et al., 1991, sequences of proteins of immunological interest, 5th ed., United States Public Health Service, National Institutes of Health, Bethesda, incorporated by reference in its entirety). "EU index of Kabat" refers to the residue numbering of the human IgG1 EU antibody as described by Edelman et al., 1969, Biochemistry 63:78-85.

[0134] The term "full-length antibody" as used herein includes structures constituting the natural biological form of an antibody, including variable and constant regions. For example, in most mammals, including humans and mice, the full-length antibody of the IgG class is a tetramer consisting of two identical pairs of paired immunoglobulin chains, each pair having a light chain and a heavy chain, each light chain comprising immunoglobulin domains VL and CL, and each heavy chain comprising immunoglobulin domains VH, CH1 (Cγ1), CH2 (Cγ2) and CH3 (Cγ3). In some mammals, such as camels and llamas, IgG antibodies may consist of only two heavy chains, each of which comprises a variable domain connected to the Fc region.

[0135] Antibody fragments include, but are not limited to: (i) Fab fragments consisting of VL, VH, CL and CH1 domains, including Fab' and Fab'-SH, (ii) Fd fragments consisting of VH and CH1 domains, (iii) Fv fragments consisting of the VL and VH domains of a single antibody; (iv) dAb fragments consisting of a single variable region; (v) F(ab')2 fragments, bivalent fragments comprising two linked Fab fragments; (vi) single-chain Fv molecule antigen binding sites; (vii) bispecific single-chain Fv dimers; (viii) "dibodies" or "tribodies", multivalent or multispecific fragments constructed by genetic fusion; and (ix) scFv genetically fused to the same or different antibodies.

[0136] According to the constant region gene determination, antibodies are classified, also known as isotypes. The constant light chain of a person is divided into K (CK) and λ (Cλ) light chains. The heavy chain is divided into μ, δ, γ, α or ε, and defines the isotypes of antibodies IgM, IgD, IgG, IgA and IgE, respectively. The IgG class is commonly used for therapeutic purposes. In humans, this category includes subclasses IgG1, IgG2, IgG3 and IgG4. In mice, this category includes subclasses IgG1, IgG2a, IgG2b and IgG3. IgM has subclasses, including but not limited to IgM1 and IgM2. IgA has several subclasses, including but not limited to IgA1 and IgA2. Thus, "isotype" used herein means any class or subclass of immunoglobulin defined by the chemical and antigenic characteristics of the constant region. Known human immunoglobulin isotypes are IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgM1, IgM2, IgD and IgE.

[0137] The term "ADCC" or "antibody-dependent cell-mediated cytotoxicity" as used herein includes a cell-mediated reaction in which nonspecific cytotoxic cells expressing FcγR recognize bound antibodies on target cells, which then lead to the lysis of the target cells. In various aspects, enhancing ADCC effector function can mean enhanced titer or enhanced efficacy. "Titer" as used in the experimental context means the concentration of the antibody when a specific therapeutic efficacy EC50 is observed (half-maximal effective concentration). "Efficacy" as used in the experimental context means the maximum possible effector function of the antibody at a saturated level.

[0138] As used herein, the term "ADCP" or "antibody-dependent cell-mediated phagocytosis" includes cells

[0139] mediated reaction in which nonspecific cytotoxic cells expressing FcγRs recognize bound antibody on a target cell, which then results in phagocytosis of the target cell.

[0140] As used herein, the term "CDC" or "complement dependent cytotoxicity" includes reactions in which one or more complement protein components recognize bound antibodies on a target cell, which then results in lysis of the target cell.

[0141] The term "effector function" as used herein includes biochemical events resulting from the interaction of an antibody Fc region with an Fc receptor or ligand. Effector functions include FcγR-mediated effector functions, such as ADCC and ADCP, and complement-mediated effector functions, such as CDC.

[0142] In this article, the selection of the body surface area formula can be based on Xu Wensheng's formula: body surface area (m2) = 0.0061 × height (cm) + 0.0128 × weight (kg) - 0.1529. Example: A person is 168cm tall and weighs 55kg. Calculate his body surface area. Solution: 0.0061 × 168 + 0.0128 × 55 - 0.1529 = 1.576m2. The body surface area calculation formulas for men and women are: S male = 0.0057 × height + 0.0121 × weight + 0.0882, S female = 0.0073 × height + 0.0127 × weight - 0.2106.

[0143] Anti-claudin 18A2 antibody

[0144] The heavy chain and light chain variable region sequences of the antibodies listed in the present invention can each bind to human claudin 18A2, and the heavy chain and light chain variable region sequences can be "mixed and matched" to generate the anti-human claudin 18A2 binding molecules of the present invention.

[0145] The present invention also provides variants of antibodies or fragments thereof that bind to human claudin 18A2. Thus, the present invention also includes antibodies or fragments thereof that have a heavy chain or light chain variable region sequence that has at least 80% amino acid sequence identity with the heavy chain and / or light chain variable region sequence of the antibody specifically disclosed in the present invention. Preferably, the amino acid sequence identity is at least 85%, more preferably at least 90%, preferably at least 95%, particularly 96%, more particularly 97%, even more particularly 98%, particularly 99%, including for example 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% and 100%. The identity of the amino acid sequence herein or the percentage of amino acid residues in the sequence that are identical to the humanized antibody or fragment thereof that binds to human claudin 18A2. Thus, sequence identity can be determined by standard methods commonly used to compare the similarity of amino acid positions of two polypeptides. Using computer programs such as BLAST or FASTA, the best match of each amino acid of the two polypeptides is compared (along the full length of one or two sequences or along a predetermined portion of one or two sequences). The program provides a default open penalty and a default gap penalty, and a scoring matrix such as PAM250 can be used in conjunction with the computer program. For example, the percentage identity can be calculated as: the total number of identical matches multiplied by 100, divided by the total length of the longer sequence in the matching span and the number of spaces poured into the longer sequence in order to align the two sequences.

[0146] In certain embodiments, framework sequences can be used to transform variable regions to produce variant antibodies. Variant antibodies of the present invention include variants in which framework residues in VH and / or VK have been modified, such as to improve the properties of the antibody. Typically, such framework modifications are performed to reduce the immunogenicity of the antibody. For example, one method is to "reverse mutate" one or more framework residues to the corresponding mouse sequence, or to "reverse mutate" one or more framework residues to the corresponding germline sequence.

[0147] Thus, in another aspect, the present invention provides a humanized antibody or fragment thereof that binds to human claudin 18A2, wherein the framework region of at least one heavy chain variable region of the humanized antibody or fragment thereof comprises at least one amino acid modification from the corresponding framework region of the heavy chain variable region of the corresponding murine antibody. Preferably, the amino acid modification is an amino acid substitution. Typically, no more than 5, preferably no more than 4, more preferably no more than 3, even more preferably no more than 2, and preferably no more than 1 amino acid modification is implemented in the framework region.

[0148] The present invention also provides humanized antibodies and fragments thereof that bind to human claudin 18A2, which also include human heavy chain and / or light chain constant domains. The human heavy chain constant region can be selected from the group of human immunoglobulins consisting of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgM1, IgM2, IgD and IgE, and the human heavy chain constant region IgG, especially IgG1 is preferred. The human light chain constant region can be selected from the group of human immunoglobulins consisting of K or λ constant regions, and the human K constant region is preferred. In some preferred embodiments, the humanized antibody or its fragment includes a human IgG1 heavy chain constant domain and a human light chain K constant domain. The present invention also provides humanized antibodies or fragments thereof that bind to human claudin 18A2, which include human heavy chain and / or light chain constant regions, wherein the human heavy chain constant region includes an isotype variant of the CH1 of human IgG1, the hinge region of human IgG1 and the Fc region of human IgG3. The preferred humanized antibody containing isotype variants is a full-length antibody. The humanized antibody or fragment thereof comprising human IgG1 comprises a heavy chain variable region sequence as shown in SEQ ID NO: 12, 14, 15, 55 or 57, and a light chain variable region sequence as shown in SEQ ID NO: 11, 13, 56 or 58. Preferably, the combination of the heavy chain variable region sequence as shown in SEQ ID NO: 12 and the light chain variable region sequence as shown in SEQ ID NO: 11; or the combination of the heavy chain variable region sequence as shown in SEQ ID NO: 14 or 15 and the light chain variable region sequence as shown in SEQ ID NO: 13; or the combination of the heavy chain variable region sequence as shown in SEQ ID NO: 55 and the light chain variable region sequence as shown in SEQ ID NO: 56.

[0149] Effector functions are typically complement dependent cytotoxicity (CDC) and / or C1q binding and / or antibody dependent cell-mediated cytotoxicity (ADCC) and / or binding affinity of the antibody to Fcγ receptors, preferably complement dependent cytotoxicity (CDC) and / or antibody dependent cell-mediated cytotoxicity (ADCC). CDC, C1q binding, ADCC and antibody binding affinity to Fcγ receptors are measured by standard in vitro assays, which are known in the art and commercially available. Typically, ADCC is measured by lactate dehydrogenase (LDH) release assays, and CDC is measured by assays administered to cells.

[0150] Standard assays for assessing the binding ability of antibodies, such as antibodies to human claudin 18A2, are known in the art and include, for example, ELISA, Western blot, and flow cytometric analysis. Suitable assays are described in detail in the Examples. To assess binding, 293T cells stably transfected with CLD18A2, AGS cells stably transfected with CLD18A2, NCI-N87 cells stably transfected with CLD18A2, BGC cells stably transfected with CLD18A2 can be used and flow cytometric analysis can be used to determine the EC50.

[0151] The preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings. The embodiments are provided to better illustrate the contents of the present invention, but the contents of the present invention are not limited to the embodiments. Those skilled in the art may make non-essential improvements and adjustments to the implementation scheme according to the above-mentioned invention contents, which belong to the protection scope of the present invention.

[0152] Example 1 Preparation of Antibodies

[0153] The antibody targeting CLD18A2 selected in this example is a humanized antibody having a heavy chain variable region as shown in SEQ ID NO: 15 and a light chain variable region as shown in SEQ ID NO: 13, the nucleotide sequence of the light chain is shown in SEQ ID NO: 60, and the nucleotide sequence of the heavy chain is shown in SEQ ID NO: 59.

[0154] The light chain and heavy chain variable regions were amplified according to the "step-out PCR" method described by Matz et al. (Nucleic Acids Research, 1999, Vol. 27, No. 6). The light chain nucleotides (sequence shown in SEQ ID NO: 60) and the heavy chain nucleotides (sequence shown in SEQ ID NO: 59) were cloned into a eukaryotic expression vector using standard methods known to those skilled in the art. 293fectin was used. TM Transfection reagent (Invitrogen, 12347-019) or polyethyleneimine (PEI) (Sigma-Aldrich, 408727) were used to transiently transfect 293F cells in the logarithmic growth phase. The culture supernatant was collected 5-7 days after transfection and affinity purified by Protein A to obtain the antibody of CLD18A2. The obtained antibody was quantitatively and qualitatively analyzed by SDS PAGE. The above-mentioned eukaryotic expression vector adopts the vector pH or vector pK adopted by CN101602808B.

[0155] Example 2 In vivo efficacy experiment of subcutaneous transplanted tumors in mouse PDX model

[0156] Gastric cancer PDX tumors of 2×2×2 mm in size were inoculated into BALB / c mice (the inoculation day was D0). The tumors were subcutaneously inoculated on D27 days, and the average tumor volume was 128 mm 3 , the human gastric cancer PDX-GA0006 model, or PDX model for short, was obtained. The tumor-bearing mice were randomly divided into 6 groups, namely, vehicle group, antibody group (Ab group), EOF group, EOF+Ab group, OF group, and OF+Ab group. The general clinical symptoms of the animals were observed during the experiment, and the body weight and tumor diameter were measured twice a week. The mice were euthanized on D51 day. The administration method was as follows:

[0157] Vehicle group: intraperitoneal injection, 3 times a week.

[0158] Ab group: CLD18A2 antibody prepared in Example 1, 40 mg / kg, intraperitoneal injection, 3 times a week.

[0159] EOF group: epirubicin hydrochloride (1.25 mg / kg) for intraperitoneal injection + oxaliplatin for injection (3.25 mg / kg) + fluorouracil injection (56.25 mg / kg) combined medication, once a week; vehicle, intraperitoneal injection, 3 times a week.

[0160] EOF+Ab group: EOF (epirubicin hydrochloride (1.25 mg / kg) + oxaliplatin for injection (3.25 mg / kg) + fluorouracil injection (56.25 mg / kg)) was given once a week, and CLD18A2 antibody (40 mg / kg) was given 3 times a week.

[0161] OF group: Oxaliplatin injection (3.25 mg / kg) + fluorouracil injection (56.25 mg / kg) combined medication, once a week; vehicle, intraperitoneal injection, 3 times a week.

[0162] OF+Ab group: OF (oxaliplatin for injection (3.25 mg / kg) + fluorouracil injection (56.25 mg / kg)) was administered once a week, and CLD18A2 antibody (40 mg / kg) was administered 3 times a week.

[0163] Tumor volume growth results Figure 1 As shown in the figure, the anti-tumor effect of the OF+Ab group was greatly enhanced when epirubicin was not used compared with the EOF+Ab group. Figure 2 As shown, the body weight of mice in the OF+Ab group was slightly better than that in the EOF+Ab group.

[0164] After the mice were euthanized, the tumors were obtained and weighed. Figure 3 , 4As shown, the tumor burden of mice in the vehicle group was too large, and one mouse died 51 days after tumor inoculation. Compared with the vehicle group, the tumor inhibition rates of each group were: Ab group, 1.21%; EOF group, 48.70%; EOF+Ab group, 69.46%; OF group, 71.64%; OF+Ab group, 96.86%, and one of the five mice in this group showed tumor regression (*p<0.05; **p<0.01 or ***p<0.001, One way ANOVA).

[0165] Example 3 Analysis of Antibody Dosage

[0166] Referring to the procedure of Example 2, different doses of antibodies were administered to tumor-bearing mice, and the specific administration methods were as follows:

[0167] 1. AB1, the CLD18A2 antibody prepared in Example 1 was administered at a dose of 40 mg / kg, intraperitoneally, 3 times a week for 2 weeks.

[0168] 2. AB2, the CLD18A2 antibody prepared in Example 1 was administered at a dose of 70 mg / kg, intraperitoneally, 3 times a week for 2 weeks.

[0169] 3. AB3, the CLD18A2 antibody prepared in Example 1 was administered at a dose of 100 mg / kg, intraperitoneally, 3 times a week for 2 weeks.

[0170] Tumor volume growth results Figure 5 As shown, the administration of AB3 group has a better anti-tumor effect. The weight change of mice is shown in Figure 6 As shown, there was no significant change in body weight, indicating that large doses of CLD18A2 antibodies have a better anti-tumor effect with minimal side effects.

[0171] In the above embodiments, illustratively, an antibody of the humanized antibody CLD18A2 is used. Those skilled in the art can use other antibodies according to the teachings of the present application, such as an antibody containing a heavy chain variable region shown in SEQ ID NO: 12 and a light chain variable region shown in SEQ ID NO: 11, or an antibody containing a heavy chain variable region shown in SEQ ID NO: 15 and a light chain variable region shown in SEQ ID NO: 13, or an antibody containing a heavy chain variable region shown in SEQ ID NO: 55 and a light chain variable region shown in SEQ ID NO: 56, or an antibody containing a heavy chain variable region shown in SEQ ID NO: 57 and a light chain variable region shown in SEQ ID NO: 58.

[0172] The sequences involved in the present invention are shown in the following table:

[0173]

[0174]

[0175] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application. Sequence Listing <110> Cogen Biopharmaceuticals (Shanghai) Co., Ltd. <120> Combination therapy of CLDN18 antibodies and chemotherapeutic drugs <130> P2019-1609 <150> CN2018111598638 <151> 2018-09-30 <150> CN2018112246053 <151> 2018-10-19 <160> 64 <170> PatentIn version 3.5 <210> 1 <211> 114 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 1 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly 1 5 10 15 Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30 Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn 85 90 95 Asp Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu 100 105 110 Lys Arg <210> 2 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Polypeptide <400> 2 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Asn Pro Ser Ser Gly Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ile Tyr Tyr Gly Asn Ser Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 3 <211> 107 <212> PRT <213> artificial sequence <220> <223> Polypeptide <400> 3 Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Ile Ser Tyr Met 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Thr Ser Pro Lys Arg Trp Ile Tyr 35 40 45 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg Ser Ser Tyr Pro Tyr Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105 <210> 4 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Polypeptide <400> 4 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Leu Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Asp Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Tyr Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asn Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Gly Gly Tyr Arg Tyr Asp Glu Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 5 <211> 114 <212> PRT <213> Synthetic sequence <220> <223> Polypeptide <400> 5 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly 1 5 10 15 Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30 Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn 85 90 95 Asp His Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu 100 105 110 Lys Arg <210> 6 <211> 118 <212> PRT <213> Synthetic sequence <220> <223> Polypeptide <400> 6 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Asn Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Phe Ser Tyr Gly Asn Ser Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 7 <211> 114 <212> PRT <213> Artificial Sequence <220> <223> Polypeptide <400> 7 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Pro Gly 1 5 10 15 Glu Lys Val Thr Met Thr Cys Lys Ser Ser Gln Ser Leu Phe Asn Ser 20 25 30 Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Arg Pro Gly Gln 35 40 45 Pro Pro Lys Met Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Phe Tyr Cys Gln Asn 85 90 95 Ala Tyr Ser Phe Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 100 105 110 Lys Arg <210> 8 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Polypeptide <400> 8 Asp Val Gln Leu Gln Glu Ser Gly Pro Asp Leu Val Lys Pro Ser Gln 1 5 10 15 Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Gly 20 25 30 Tyr Asn Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Met Glu Trp 35 40 45 Met Gly Tyr Ile His Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ser Leu 50 55 60 Arg Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 65 70 75 80 Leu Gln Leu Asn Ser Val Thr Thr Asp Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Thr Arg Ile Tyr Asn Gly Asn Ser Phe Pro Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 9 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Polypeptide <400> 9 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Asp Pro Ser Ser Gly Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ile Tyr Tyr Gly Asn Ser Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 10 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Polypeptide <400> 10 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Asn Pro Ala Ser Gly Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ile Tyr Tyr Gly Asn Ser Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 11 <211> 114 <212> PRT <213> Artificial Sequence <220> <223> Polypeptide <400> 11 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30 Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Asn 85 90 95 Asp Tyr Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 100 105 110 Lys Arg <210> 12 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Polypeptide <400> 12 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Tyr Ile Asn Pro Ala Ser Gly Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ile Tyr Tyr Gly Asn Ser Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 13 <211> 114 <212> PRT <213> artificial sequence <220> <223> Polypeptide <400> 13 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Phe Asn Ser 20 25 30 Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Asn 85 90 95 Ala Tyr Ser Phe Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 100 105 110 Lys Arg <210> 14 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Polypeptide <400> 14 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly 20 25 30 Tyr Asn Trp His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Ile Gly Tyr Ile His Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ala Leu 50 55 60 Arg Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ile Tyr Asn Gly Asn Ser Phe Pro Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 15 <211> 118 <212> PRT <213> Artificial sequence <220> <223> Polypeptide <400> 15 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Ile Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly 20 25 30 Tyr Asn Trp His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Ile Gly Tyr Ile His Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ala Leu 50 55 60 Arg Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg Ile Tyr Asn Gly Asn Ser Phe Pro Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 16 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 16 Ser Tyr Thr Met His 1 5 <210> 17 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 17 Tyr Ile Asn Pro Ser Ser Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys 1 5 10 15 Asp <210> 18 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 18 Ile Tyr Tyr Gly Asn Ser Phe Ala Tyr 1 5 <210> 19 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 19 Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu 1 5 10 15 Thr <210> 20 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 20 Trp Ala Ser Thr Arg Glu Ser 1 5 <210> twenty one <211> 9 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> twenty one Gln Asn Asp Tyr Ser Tyr Pro Leu Thr 1 5 <210> twenty two <211> 5 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> twenty two Ser Tyr Asp Ile Asn 1 5 <210> twenty three <211> 17 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> twenty three Trp Ile Tyr Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe Lys 1 5 10 15 Gly <210> twenty four <211> 11 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> twenty four Gly Gly Tyr Arg Tyr Asp Glu Ala Met Asp Tyr 1 5 10 <210> 25 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 25 Ser Ala Ser Ser Ser Ser Ile Ser Tyr Met His 1 5 10 <210> 26 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 26 Asp Thr Ser Lys Leu Ala Ser 1 5 <210> 27 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 27 His Gln Arg Ser Ser Tyr Pro Tyr Thr 1 5 <210> 28 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 28 Asn Tyr Gly Met Asn 1 5 <210> 29 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 29 Trp Ile Asn Thr Asn Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys 1 5 10 15 Gly <210> 30 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 30 Phe Ser Tyr Gly Asn Ser Phe Ala Tyr 1 5 <210> 31 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 31 Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu 1 5 10 15 Ala <210> 32 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 32 Gly Ala Ser Thr Arg Glu Ser 1 5 <210> 33 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 33 Gln Asn Asp His Ser Tyr Pro Leu Thr 1 5 <210> 34 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 34 Ser Gly Tyr Asn Trp His 1 5 <210> 35 <211> 16 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 35 Tyr Ile His Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ser Leu Arg Ser 1 5 10 15 <210> 36 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 36 Ile Tyr Asn Gly Asn Ser Phe Pro Tyr 1 5 <210> 37 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 37 Lys Ser Ser Gln Ser Leu Phe Asn Ser Gly Asn Gln Lys Asn Tyr Leu 1 5 10 15 Thr <210> 38 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 38 Trp Ala Ser Thr Arg Glu Ser 1 5 <210> 39 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 39 Gln Asn Ala Tyr Ser Phe Pro Tyr Thr 1 5 <210> 40 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 40 Tyr Ile Asp Pro Ser Ser Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys 1 5 10 15 Asp <210> 41 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 41 Tyr Ile Asn Pro Ala Ser Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys 1 5 10 15 Asp <210> 42 <211> 16 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 42 Tyr Ile His Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ala Leu Arg Ser 1 5 10 15 <210> 43 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 43 Ser Tyr Trp Ile Asn 1 5 <210> 44 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 44 Asn Ile Tyr Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe Lys 1 5 10 15 Asp <210> 45 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 45 Ser Trp Arg Gly Asn Ser Phe Asp Tyr 1 5 <210> 46 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 46 Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu 1 5 10 15 Thr <210> 47 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 47 Trp Ala Ser Thr Arg Glu Ser 1 5 <210> 48 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 48 Gln Asn Asp Tyr Ser Tyr Pro Phe Thr 1 5 <210> 49 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 49 Asn Tyr Gly Met Asn 1 5 <210> 50 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 50 Trp Ile Asn Thr Asn Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys 1 5 10 15 Gly <210> 51 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 51 Leu Gly Phe Gly Asn Ala Met Asp Tyr 1 5 <210> 52 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 52 Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu 1 5 10 15 Thr <210> 53 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 53 Trp Ala Ser Thr Arg Glu Ser 1 5 <210> 54 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 54 Gln Asn Asp Tyr Ser Tyr Pro Leu Thr 1 5 <210> 55 <211> 118 <212> PRT <213> Artificial sequence <220> <223> Peptides <400> 55 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Tyr Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Ser Trp Arg Gly Asn Ser Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser 115 <210> 56 <211> 114 <212> PRT <213> Artificial Sequence <220> <223> Polypeptide <400> 56 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly 1 5 10 15 Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30 Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn 85 90 95 Asp Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 100 105 110 Lys Arg <210> 57 <211> 114 <212> PRT <213> Artificial Sequence <220> <223> Polypeptide <400> 57 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly 1 5 10 15 Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30 Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn 85 90 95 Asp Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu 100 105 110 Lys Arg <210> 58 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Polypeptide <400> 58 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Asn Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Leu Gly Phe Gly Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 59 <211> 1344 <212> DNA <213> Artificial Sequence <220> <223> Polynucleotide <400> 59 caggtgcagc tgcaggagag cggccccggc ctgatcaagc ccagccagac cctgagcctg 60 acctgcaccg tgagcggcgg cagcatcagc agcggctaca actggcactg gatccggcag 120 ccccccggca agggcctgga gtggatcggc tacatccact acaccggcag caccaactac 180 aaccccgccc tgcggagccg ggtgaccatc agcgtggaca ccagcaagaa ccagttcagc 240 ctgaagctga gcagcgtgac cgccgccgac accgccatct actactgcgc ccggatctac 300 aacggcaaca gcttccccta ctggggccag ggcaccaccg tgaccgtgag cagcgctagc 360 accaaaggcc catcggtctt ccccctggca ccctcctcca agagcacctc tgggggcaca 420 gcggccctgg gctgcctggt caaggactac ttccccgaac cggtgacggt gtcgtggaac 480 tcaggcgccc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc 540 tactccctca gcagcgtggt gaccgtgccc tccagcagct tgggcaccca gacctacatc 600 tgcaacgtga atcacaagcc cagcaacacc aaggtggaca agaaagttga gcccaaatct 660 tgtgacaaaa ctcacacatg cccaccgtgc ccagcacctg aactcctggg gggaccgtca 720 gtttctctct tccccccaaa acccaaggac accctcatga tctcccggac ccctgaggtc 780 acatgcgtgg tggtggacgt gagccacgaa gaccctgagg tcaagttcaa ctggtacgtg 840 gacggcgtgg aggtgcataa tgccaagaca aagccgcggg aggagcagta caacagcacg 900 taccgtgtgg tcagcgtcct caccgtcctg caccaggact ggctgaatgg caaggagtac 960 aagtgcaagg tctccaacaa agccctccca gcccccatcg agaaaaccat ctccaaagcc 1020 aaagggcagc cccgagaacc acaggtgtac accctgcccc catcccggga tgagctgacc 1080 aagaaccagg tcagcctgac ctgcctggtc aaaggcttct atcccagcga catcgccgtg 1140 gagtgggaga gcaatgggca gccggagaac aactacaaga ccacgcctcc cgtgctggac 1200 tccgacggct ccttcttcct ctatagcaag ctcaccgtgg acaagagcag gtggcagcag 1260 gggaacgtct tctcatgctc cgtgatgcat gaggctctgc acaaccacta cacgcagaag 1320 agcctctccc tgtctccggg taaa 1344 <210> 60 <211> 660 <212> DNA <213> Artificial sequence <220> <223> Polynucleotide <400> 60 gacatcgtga tgacccagag ccccgacagc ctggccgtga gcctgggcga gcgggccacc 60 atcaactgca agagcagcca gagcctgttc aacagcggca accagaagaa ctacctgacc 120 tggtaccagc agaagcccgg ccagcccccc aagctgctga tctactgggc cagcacccgg 180 gagagcggcg tgcccgaccg gttcagcggc agcggcagcg gcaccgactt caccctgacc 240 atcagcagcc tgcaggccga ggacgtggcc gtgtactact gccagaacgc ctacagcttc 300 ccctacacct tcggcggcgg caccaagctg gagatcaagc ggacggtggc tgcaccatct 360 gtcttcatct tcccgccatc tgatgagcag ttgaaatctg gaactgcctc tgttgtgtgc 420 ctgctgaata acttctatcc cagagaggcc aaagtacagt ggaaggtgga taacgccctc 480 caatcgggta actcccagga gagtgtcaca gagcaggaca gcaaggacag cacctacagc 540 ctcagcagca ccctgacgct gagcaaagca gactacgaga aacacaaagt ctacgcctgc 600 gaagtcaccc atcagggcct gagctcgccc gtcacaaaga gcttcaacag gggagagtgt 660 <210> 61 <211> 220 <212> PRT <213> Artificial Sequence <220> <223> Polypeptide <400> 61 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly 1 5 10 15 Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30 Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn 85 90 95 Asp Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu 100 105 110 Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 115 120 125 Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 130 135 140 Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu 145 150 155 160 Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp 165 170 175 Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr 180 185 190 Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser 195 200 205 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 220 <210> 62 <211> 448 <212> PRT <213> Artificial sequence <220> <223> Polypeptide <400> 62 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Asn Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Leu Gly Phe Gly Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 63 <211> 220 <212> PRT <213> Artificial Sequence <220> <223> Polypeptide <400> 63 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly 1 5 10 15 Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30 Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn 85 90 95 Asp Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 100 105 110 Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 115 120 125 Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 130 135 140 Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu 145 150 155 160 Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp 165 170 175 Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr 180 185 190 Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser 195 200 205 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 220 <210> 64 <211> 448 <212> PRT <213> Artificial Sequence <220> <223> Polypeptide <400> 64 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Tyr Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Ser Trp Arg Gly Asn Ser Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445

Claims

1. Use of a combination of an antibody that specifically recognizes CLDN18 and a chemotherapeutic drug in the preparation of a drug for treating CLDN18-positive tumors, characterized in that: The chemotherapy drug does not include epirubicin; The chemotherapy drugs are: 5-fluorouracil or a prodrug thereof, and oxaliplatin or a prodrug thereof; The antibody specifically recognizes CLDN18.2; the antibody specifically recognizing CLDN18.2 has: HCDR1 as shown in the amino acid sequence of SEQ ID NO: 34, HCDR2 as shown in the amino acid sequence of SEQ ID NO: 42, HCDR3 as shown in the amino acid sequence of SEQ ID NO: 36, and LCDR1 as shown in the amino acid sequence of SEQ ID NO: 37, LCDR2 as shown in the amino acid sequence of SEQ ID NO: 38, and LCDR3 as shown in the amino acid sequence of SEQ ID NO: 39; The CLDN18-positive tumors include gastric cancer, pancreatic cancer, esophageal cancer and lung cancer.

2. The use according to claim 1, characterized in that The prodrug of 5-fluorouracil is capecitabine.

3. The use according to claim 1 or 2, characterized in that The chemotherapy drug and the CLDN18 antibody are administered in any order.

4. The use according to claim 3, characterized in that The chemotherapy drug is administered first, and then the CLDN18 antibody is administered.

5. The use according to claim 4, characterized in that The chemotherapeutic drug and the CLDN18 antibody are administered on the same day; or, the CLDN18 antibody is administered at least one day after the chemotherapeutic drug is administered.

6. The use according to claim 1, characterized in that: The dosage of the CLDN18 antibody is 500 to 1200 mg / m 2 / Second-rate.

7. The use according to claim 6, characterized in that The dosage of the CLDN18 antibody is 500-1000 mg / m 2 / Second-rate.

8. The use according to claim 7, characterized in that The dosage of the CLDN18 antibody is 500-900 mg / m 2 / Second-rate.

9. The use according to claim 8, characterized in that The dosage of the CLDN18 antibody is 600-800 mg / m 2 / Second-rate.

10. The use according to claim 1, characterized in that The administration dose of the CLDN18 antibody is 20 to 300 mg / kg / time.

11. The use according to claim 10, characterized in that The administration dose of the CLDN18 antibody is 20 to 100 mg / kg / time.

12. The use according to claim 11, characterized in that The administration dose of the CLDN18 antibody is 20-50 mg / kg / time.

13. The use according to claim 1, characterized in that The dosage of 5-fluorouracil or its prodrug or its active metabolite is 300-900 mg / m 2 / Second-rate.

14. The use according to claim 13, characterized in that Give 5-fluorouracil at a dose of 300-800 mg / m 2 / time; or, give capecitabine 600-700 mg / m 2 / Second-rate.

15. The use according to claim 14, characterized in that Capecitabine 625 mg / m 2 / Second-rate.

16. The use according to claim 1, characterized in that The administration dosage of the 5-fluorouracil or its prodrug or its active metabolite is 50-70 mg / kg / time.

17. The use according to claim 16, characterized in that Administer 5-fluorouracil at a dosage of 50 to 70 mg / kg / time.

18. The use according to claim 17, characterized in that The dosage of 5-fluorouracil is 50-60 mg / kg / time.

19. The use according to claim 1, characterized in that The dosage of oxaliplatin or its prodrug or its active metabolite is 50-300 mg / m 2 / Second-rate.

20. The use according to claim 14, characterized in that Give oxaliplatin 100–200 mg / m 2 / Second-rate.

21. The use according to claim 20, characterized in that Give oxaliplatin 130 mg / m 2 / Second-rate.

22. The use according to claim 1, characterized in that The administration dosage of oxaliplatin or its prodrug or its active metabolite is 1 to 10 mg / kg / time.

23. The use according to claim 22, characterized in that Give oxaliplatin 1-5 mg / kg / time.

24. The use according to claim 1, characterized in that The antibody is a humanized antibody or a chimeric antibody.

25. The use according to claim 1, characterized in that The antibody that specifically recognizes CLDN18 comprises: The heavy chain variable region is shown in the amino acid sequence of SEQ ID NO: 14 or 15, and the light chain variable region is shown in the amino acid sequence of SEQ ID NO:

13.

26. The use according to claim 25, characterized in that The antibody is selected from: (a) has a heavy chain encoded by the nucleotide sequence shown in SEQ ID NO:59 and a light chain encoded by the nucleotide sequence shown in SEQ ID NO:

60.

27. The use according to claim 1, characterized in that The CLDN18-positive tumor is gastric cancer.